NASDAQ:CMPI

Checkmate Pharmaceuticals Competitors

$10.57
+0.09 (+0.86 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.52
Now: $10.57
$11.00
50-Day Range
$10.38
MA: $13.39
$15.00
52-Week Range
$8.61
Now: $10.57
$23.10
Volume38,000 shs
Average Volume42,416 shs
Market Capitalization$228.50 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Checkmate Pharmaceuticals (NASDAQ:CMPI) Vs. BDTX, ADVM, AERI, PASG, CLLS, and TCRR

Should you be buying CMPI stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Checkmate Pharmaceuticals, including Black Diamond Therapeutics (BDTX), Adverum Biotechnologies (ADVM), Aerie Pharmaceuticals (AERI), Passage Bio (PASG), Cellectis (CLLS), and TCR2 Therapeutics (TCRR).

Checkmate Pharmaceuticals (NASDAQ:CMPI) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership.

Profitability

This table compares Checkmate Pharmaceuticals and Black Diamond Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Checkmate PharmaceuticalsN/AN/A-57.12%
Black Diamond TherapeuticsN/A-22.28%-17.91%

Earnings and Valuation

This table compares Checkmate Pharmaceuticals and Black Diamond Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Checkmate PharmaceuticalsN/AN/A$-28,290,000.00N/AN/A
Black Diamond TherapeuticsN/AN/A$-35,260,000.00($16.99)-1.45

Insider and Institutional Ownership

75.6% of Checkmate Pharmaceuticals shares are held by institutional investors. Comparatively, 65.8% of Black Diamond Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Checkmate Pharmaceuticals and Black Diamond Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Checkmate Pharmaceuticals01302.75
Black Diamond Therapeutics00403.00

Checkmate Pharmaceuticals presently has a consensus target price of $24.75, suggesting a potential upside of 134.15%. Black Diamond Therapeutics has a consensus target price of $51.50, suggesting a potential upside of 109.09%. Given Checkmate Pharmaceuticals' higher probable upside, equities analysts plainly believe Checkmate Pharmaceuticals is more favorable than Black Diamond Therapeutics.

Summary

Checkmate Pharmaceuticals beats Black Diamond Therapeutics on 4 of the 7 factors compared between the two stocks.

Checkmate Pharmaceuticals (NASDAQ:CMPI) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Checkmate Pharmaceuticals and Adverum Biotechnologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Checkmate Pharmaceuticals01302.75
Adverum Biotechnologies02802.80

Checkmate Pharmaceuticals presently has a consensus target price of $24.75, suggesting a potential upside of 134.15%. Adverum Biotechnologies has a consensus target price of $23.50, suggesting a potential upside of 158.81%. Given Adverum Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe Adverum Biotechnologies is more favorable than Checkmate Pharmaceuticals.

Profitability

This table compares Checkmate Pharmaceuticals and Adverum Biotechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Checkmate PharmaceuticalsN/AN/A-57.12%
Adverum BiotechnologiesN/A-32.23%-28.02%

Earnings and Valuation

This table compares Checkmate Pharmaceuticals and Adverum Biotechnologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Checkmate PharmaceuticalsN/AN/A$-28,290,000.00N/AN/A
Adverum Biotechnologies$250,000.003,551.95$-64,490,000.00($1.01)-8.99

Checkmate Pharmaceuticals has higher earnings, but lower revenue than Adverum Biotechnologies.

Insider and Institutional Ownership

75.6% of Checkmate Pharmaceuticals shares are held by institutional investors. Comparatively, 97.4% of Adverum Biotechnologies shares are held by institutional investors. 12.4% of Adverum Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Adverum Biotechnologies beats Checkmate Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

Aerie Pharmaceuticals (NASDAQ:AERI) and Checkmate Pharmaceuticals (NASDAQ:CMPI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Aerie Pharmaceuticals and Checkmate Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aerie Pharmaceuticals11802.70
Checkmate Pharmaceuticals01302.75

Aerie Pharmaceuticals currently has a consensus price target of $23.8889, indicating a potential upside of 26.87%. Checkmate Pharmaceuticals has a consensus price target of $24.75, indicating a potential upside of 134.15%. Given Checkmate Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Checkmate Pharmaceuticals is more favorable than Aerie Pharmaceuticals.

Profitability

This table compares Aerie Pharmaceuticals and Checkmate Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aerie Pharmaceuticals-231.05%-135.57%-37.23%
Checkmate PharmaceuticalsN/AN/A-57.12%

Earnings & Valuation

This table compares Aerie Pharmaceuticals and Checkmate Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aerie Pharmaceuticals$69.89 million12.64$-199,580,000.00($3.40)-5.54
Checkmate PharmaceuticalsN/AN/A$-28,290,000.00N/AN/A

Checkmate Pharmaceuticals has lower revenue, but higher earnings than Aerie Pharmaceuticals.

Insider & Institutional Ownership

99.9% of Aerie Pharmaceuticals shares are held by institutional investors. Comparatively, 75.6% of Checkmate Pharmaceuticals shares are held by institutional investors. 9.7% of Aerie Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Passage Bio (NASDAQ:PASG) and Checkmate Pharmaceuticals (NASDAQ:CMPI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Passage Bio and Checkmate Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Passage Bio02502.71
Checkmate Pharmaceuticals01302.75

Passage Bio currently has a consensus price target of $27.3154, indicating a potential upside of 67.17%. Checkmate Pharmaceuticals has a consensus price target of $24.75, indicating a potential upside of 134.15%. Given Checkmate Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Checkmate Pharmaceuticals is more favorable than Passage Bio.

Profitability

This table compares Passage Bio and Checkmate Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Passage BioN/AN/AN/A
Checkmate PharmaceuticalsN/AN/A-57.12%

Earnings & Valuation

This table compares Passage Bio and Checkmate Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Passage BioN/AN/AN/AN/AN/A
Checkmate PharmaceuticalsN/AN/A$-28,290,000.00N/AN/A

Insider & Institutional Ownership

67.6% of Passage Bio shares are held by institutional investors. Comparatively, 75.6% of Checkmate Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Checkmate Pharmaceuticals beats Passage Bio on 3 of the 5 factors compared between the two stocks.

Cellectis (NASDAQ:CLLS) and Checkmate Pharmaceuticals (NASDAQ:CMPI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability.

Insider & Institutional Ownership

33.3% of Cellectis shares are held by institutional investors. Comparatively, 75.6% of Checkmate Pharmaceuticals shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Cellectis and Checkmate Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectis$22.99 million37.07$-102,090,000.00($2.41)-8.27
Checkmate PharmaceuticalsN/AN/A$-28,290,000.00N/AN/A

Checkmate Pharmaceuticals has lower revenue, but higher earnings than Cellectis.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Cellectis and Checkmate Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cellectis00403.00
Checkmate Pharmaceuticals01302.75

Cellectis currently has a consensus price target of $34.6667, indicating a potential upside of 74.03%. Checkmate Pharmaceuticals has a consensus price target of $24.75, indicating a potential upside of 134.15%. Given Checkmate Pharmaceuticals' higher probable upside, analysts clearly believe Checkmate Pharmaceuticals is more favorable than Cellectis.

Profitability

This table compares Cellectis and Checkmate Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cellectis-110.52%-23.56%-16.69%
Checkmate PharmaceuticalsN/AN/A-57.12%

Checkmate Pharmaceuticals (NASDAQ:CMPI) and TCR2 Therapeutics (NASDAQ:TCRR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

75.6% of Checkmate Pharmaceuticals shares are owned by institutional investors. Comparatively, 82.1% of TCR2 Therapeutics shares are owned by institutional investors. 28.0% of TCR2 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Checkmate Pharmaceuticals and TCR2 Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Checkmate PharmaceuticalsN/AN/A$-28,290,000.00N/AN/A
TCR2 TherapeuticsN/AN/A$-47,600,000.00($4.62)-4.77

Analyst Recommendations

This is a summary of recent recommendations for Checkmate Pharmaceuticals and TCR2 Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Checkmate Pharmaceuticals01302.75
TCR2 Therapeutics00803.00

Checkmate Pharmaceuticals currently has a consensus price target of $24.75, indicating a potential upside of 134.15%. TCR2 Therapeutics has a consensus price target of $43.2857, indicating a potential upside of 96.57%. Given Checkmate Pharmaceuticals' higher probable upside, equities analysts clearly believe Checkmate Pharmaceuticals is more favorable than TCR2 Therapeutics.

Profitability

This table compares Checkmate Pharmaceuticals and TCR2 Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Checkmate PharmaceuticalsN/AN/A-57.12%
TCR2 TherapeuticsN/A-35.51%-34.02%

Summary

TCR2 Therapeutics beats Checkmate Pharmaceuticals on 5 of the 8 factors compared between the two stocks.


Checkmate Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$24.63+0.9%$890.08 millionN/A-4.07
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$9.08+6.9%$887.99 million$250,000.00-7.15
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$18.83+0.7%$883.45 million$69.89 million-4.49
Passage Bio logo
PASG
Passage Bio
1.8$16.34+4.4%$879.60 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.3$19.92+1.6%$852.18 million$22.99 million-10.60
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$22.02+2.8%$839.78 millionN/A-9.10Analyst Report
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.73+3.7%$832.47 million$2.51 million-4.08
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.47+5.4%$818.93 millionN/A0.00Lockup Expiration
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$21.19+6.0%$800.16 millionN/A0.00
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$5.05+1.6%$785.11 million$1.12 million-5.10
Inhibrx logo
INBX
Inhibrx
1.6$20.50+0.4%$773.83 millionN/A0.00
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$22.67+0.3%$734.76 million$5.78 million-10.64
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.08+2.3%$708.25 millionN/A0.00
Vaxart logo
VXRT
Vaxart
1.3$5.53+2.5%$651.25 million$9.86 million-9.37
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.74+3.3%$630.67 million$14.75 million-2.46
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.35+3.3%$590.92 million$13.29 million-9.47
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.5$28.56+1.2%$585.57 millionN/A0.00Lockup Expiration
Compugen logo
CGEN
Compugen
1.4$8.42+0.0%$576.10 million$17.80 million-22.76Analyst Revision
Agenus logo
AGEN
Agenus
1.6$2.78+0.4%$570.05 million$150.05 million-2.55
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$5.21+3.1%$556.83 millionN/A-2.53Gap Down
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.8$8.90+0.6%$552.76 millionN/A-1.30Gap Down
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.0$20.48+2.5%$530.64 millionN/A-5.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$8.60+3.6%$490.08 million$22.24 million-4.28
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.6$13.23+5.1%$474.60 millionN/A0.00
AVROBIO logo
AVRO
AVROBIO
1.7$11.32+2.5%$471.16 millionN/A-3.43
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$5.25+1.5%$466.41 millionN/A-8.20
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$9.10+1.4%$445.46 million$4.36 million-3.18Analyst Upgrade
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$9.78+6.6%$443.95 million$147.87 million-3.25News Coverage
Opthea logo
OPT
Opthea
1.5$9.66+1.2%$419.80 millionN/A0.00Lockup Expiration
News Coverage
Gap Down
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$9.51+6.4%$397.95 millionN/A0.00
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.66+1.0%$380.70 millionN/A0.00
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$2.19+2.7%$380.20 million$8.15 million-1.75
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.27+2.3%$348.11 million$250,000.00-3.31
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$15.49+6.2%$340.69 millionN/A0.00Lockup Expiration
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.26+2.1%$336.50 million$96.12 million-12.53Analyst Revision
Surface Oncology logo
SURF
Surface Oncology
1.4$7.95+2.8%$331.74 million$15.36 million-12.05Analyst Report
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.3$5.60+3.4%$293.14 million$2.91 million-1.95
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$8.40+1.8%$284.77 millionN/A-3.46
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$2.03+1.0%$283.79 million$4.13 million-4.51
PDL BioPharma logo
PDLI
PDL BioPharma
0.8$2.47+9.3%$282.14 million$54.76 million-2.19High Trading Volume
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$10.76+0.7%$258.92 millionN/A-7.85
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.76+6.3%$213.44 million$29.35 million-2.05
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$6.16+2.9%$197.28 millionN/A-3.85
Gamida Cell logo
GMDA
Gamida Cell
1.4$7.83+3.2%$189.64 millionN/A-5.48
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$4.41+3.6%$188.54 million$2.45 million-2.07
Genfit logo
GNFT
Genfit
1.3$4.62+0.4%$179.53 million$45.88 million-2.35
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$4.76+0.2%$179.23 million$104.39 million-2.90
INmune Bio logo
INMB
INmune Bio
1.5$11.77+3.2%$175.76 millionN/A-12.13
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$14.95+3.3%$167.87 millionN/A0.00
Axcella Health logo
AXLA
Axcella Health
1.6$4.34+5.5%$163.58 millionN/A-2.02
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.